Why the study?
Does intravenous levosimendan improve clinical outcomes and cost-effectiveness compared to dobutamine in patients with acute heart failure?
Population
292 patients with acute heart failure derived from an observational registry
Comparison
Intravenous levosimendan vs Standard inotropic therapy of dobutamine
Design
Cohort
Follow-up
12 months
Authors
Loading...
May favor levosimendan over dobutamine in acute HF; hypothesis-generating and requires RCT confirmation before practice change.
Does intravenous levosimendan improve clinical outcomes and cost-effectiveness compared to dobutamine in patients with acute heart failure?
Levosimendan appears to be more cost-effective than dobutamine in acute heart failure due to reduced length of stay, lower mortality, and decreased rehospitalization rates.
Fedele et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: